Literature DB >> 24718924

The tumor suppressor PTEN interacts with p53 in hereditary cancer (Review).

Atsuko Nakanishi1, Yasuko Kitagishi1, Yasunori Ogura1, Satoru Matsuda1.   

Abstract

Numerous hereditary syndromes caused by mutations in multiple tumor suppressor genes can cause cancers. Germline mutations in PTEN and p53 tumor suppressor cause Cowden syndrome and Li-Fraumeni syndrome, respectively. There exists some phenotypic overlap in these syndromes, and they are associated with high risks of breast cancer. The tumor suppressor protein PTEN is a dual-specificity phosphatase which has protein phosphatase activity and lipid phosphatase activity that antagonizes PI3K activity. Cells that lack PTEN have constitutively higher levels of PIP3 and activated downstream targets. PTEN gene is recognized as one of the most frequently mutated or mutated in many human cancers. Li-Fraumeni syndrome results from germline mutations of the tumor suppressor p53 gene encoding a transcriptional factor able to regulate cell cycle and apoptosis when DNA damage occurs. The p53 protein cooperates with PTEN and might be an essential blockage in development of mammary tumors. Many findings have demonstrated that PTEN as well as p53 plays a critical role in DNA damage response. This review summarizes the function of PTEN and p53 in carcinogenic cell signaling. In addition, we will discuss the role of PTEN signaling through its interaction with p53 and MDM2 pathways for the potential implications in hereditary cancer prevention and therapeutic intervention.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24718924     DOI: 10.3892/ijo.2014.2377

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  19 in total

1.  Inhibition of miRNA-21 attenuates the proliferation and metastasis of human osteosarcoma by upregulating PTEN.

Authors:  Chen Li; Binwu Xu; Xinxin Miu; Zhongbo Deng; Hang Liao; Liang Hao
Journal:  Exp Ther Med       Date:  2017-11-10       Impact factor: 2.447

Review 2.  Taurine and Its Anticancer Functions: In Vivo and In Vitro Study.

Authors:  Ning Ma; Feng He; Jun Kawanokuchi; Guifeng Wang; Takenori Yamashita
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 3.650

3.  Expression of PTEN and KAI1 tumor suppressor genes in pancreatic carcinoma and its association with different pathological factors.

Authors:  Weidong Huang; Jie Yang; Jun Ren; Jianjun Tang
Journal:  Oncol Lett       Date:  2015-11-17       Impact factor: 2.967

4.  MicroRNA-20a-5p contributes to hepatic glycogen synthesis through targeting p63 to regulate p53 and PTEN expression.

Authors:  Weiwei Fang; Jun Guo; Yuan Cao; Shuyue Wang; Cheng Pang; Meng Li; Lin Dou; Yong Man; Xiuqing Huang; Tao Shen; Jian Li
Journal:  J Cell Mol Med       Date:  2016-03-28       Impact factor: 5.310

Review 5.  VSV based virotherapy in ovarian cancer: the past, the present and …future?

Authors:  Beata Urszula Orzechowska; Marcin Jędryka; Katarzyna Zwolińska; Rafał Matkowski
Journal:  J Cancer       Date:  2017-07-22       Impact factor: 4.207

6.  Pharmacophore modeling for identification of anti-IGF-1R drugs and in-vitro validation of fulvestrant as a potential inhibitor.

Authors:  Samra Khalid; Rumeza Hanif; Ishrat Jabeen; Qaisar Mansoor; Muhammad Ismail
Journal:  PLoS One       Date:  2018-05-22       Impact factor: 3.240

Review 7.  PTEN as a Therapeutic Target in Pulmonary Hypertension Secondary to Left-heart Failure: Effect of HO-3867 and Supplemental Oxygenation.

Authors:  Yazhini Ravi; Chittoor B Sai-Sudhakar; Periannan Kuppusamy
Journal:  Cell Biochem Biophys       Date:  2021-06-16       Impact factor: 2.194

8.  Treatment-associated TP53 DNA-binding domain missense mutations in the pathogenesis of secondary gliosarcoma.

Authors:  Margaret Pain; Huaien Wang; Eunjee Lee; Maya Strahl; Wissam Hamou; Robert Sebra; Jun Zhu; Raymund L Yong
Journal:  Oncotarget       Date:  2017-12-20

Review 9.  PTEN/PTENP1: 'Regulating the regulator of RTK-dependent PI3K/Akt signalling', new targets for cancer therapy.

Authors:  Nahal Haddadi; Yiguang Lin; Glena Travis; Ann M Simpson; Najah T Nassif; Eileen M McGowan
Journal:  Mol Cancer       Date:  2018-02-19       Impact factor: 27.401

10.  The effect of endurance training with and without vitamin E on expression of p53 and PTEN tumor suppressing genes in prostate glands of male rats.

Authors:  Amin Allah Dashtiyan; Masood Sepehrimanesh; Nader Tanideh; Mohammad Esmaeil Afzalpour
Journal:  Biochim Open       Date:  2017-04-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.